19T Stock Chart & Stats
€6.02
-€0.15(-2.25%)
At close: 4:00 PM EDT
€6.02
-€0.15(-2.25%)
Day’s Range― - ―
52-Week Range€3.18 - €8.09
Previous CloseN/A
Volume0.00
Average Volume (3M)64.00
Market Cap
€1.21B
Enterprise Value€3.01B
Total Cash (Recent Filing)€88.69M
Total Debt (Recent Filing)€1.32B
Price to Earnings (P/E)―
Beta-0.38
Next Earnings
Oct 29, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding269,779,600
10 Day Avg. Volume70
30 Day Avg. Volume64
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-0.80
Price to Sales (P/S)4.14
P/FCF Ratio-5.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.18Price Target Upside2.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.67
Revenue Forecast (FY)€231.38M
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginAn approximately 81% gross margin indicates that Idorsia’s products can generate substantial gross profit before operating costs. If the company improves commercialization and controls development spending, this product economics could support better operating leverage over the next several quarters.
Proprietary Drug PipelineA proprietary small-molecule pipeline across multiple therapeutic areas provides potential sources of future product revenue and reduces reliance on a single candidate. Successful development or commercialization could create durable intellectual-property-based opportunities over the medium term.
Partnership And Licensing ModelLicensing and collaboration arrangements give Idorsia additional ways to monetize research beyond direct product sales. Upfront payments, milestones, and royalties can provide non-linear funding and future revenue opportunities when partnered medicines advance or reach commercial markets.
Bears Say
Stressed Balance SheetMaterially negative equity and debt that is large relative to the asset base indicate severe financial strain. This weakens flexibility to fund research and commercialization internally, while increasing dependence on refinancing, asset actions, or external capital over coming quarters.
Persistent Cash BurnSustained negative operating and free cash flow means the business is consuming cash rather than self-funding its pipeline and operations. If this pattern persists, ongoing funding needs could constrain investment choices and increase pressure on the already stressed balance sheet.
Deep Losses And Revenue DeclineFalling revenue alongside extremely negative operating and net margins shows that Idorsia has not yet converted its product and pipeline activities into a sustainable earnings engine. Continued losses could limit reinvestment capacity and prolong reliance on funding or partnerships.
19T FAQ
What was Idorsia Ltd’s price range in the past 12 months?
Idorsia Ltd lowest stock price was €3.18 and its highest was €8.09 in the past 12 months.
What is Idorsia Ltd’s market cap?
Idorsia Ltd’s market cap is €1.21B.
When is Idorsia Ltd’s upcoming earnings report date?
Idorsia Ltd’s upcoming earnings report date is Oct 29, 2026 which is in 18 days.
How were Idorsia Ltd’s earnings last quarter?
Idorsia Ltd released its earnings results on Jul 30, 2026. The company reported -€0.183 earnings per share for the quarter, beating the consensus estimate of -€0.21 by €0.027.
Is Idorsia Ltd overvalued?
According to Wall Street analysts Idorsia Ltd’s price is currently Undervalued.
Does Idorsia Ltd pay dividends?
Idorsia Ltd does not currently pay dividends.
What is Idorsia Ltd’s EPS estimate?
Idorsia Ltd’s EPS estimate is -0.3.
How many shares outstanding does Idorsia Ltd have?
Idorsia Ltd has 269,779,600 shares outstanding.
What happened to Idorsia Ltd’s price movement after its last earnings report?
Idorsia Ltd reported an EPS of -€0.183 in its last earnings report, beating expectations of -€0.21. Following the earnings report the stock price went down -2.059%.
Which hedge fund is a major shareholder of Idorsia Ltd?
Currently, no hedge funds are holding shares in DE:19T
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company’s product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat fabry disease; Daridorexant, a dual orexin receptor antagonist, which is in phase 2 clinical trial for the treatment of pediatric insomnia; IDOR-1117-2520, a CCR6 receptor antagonist which is in phase 1 clinical program to treat psoriasis; ACT-777991, a CXCR3 antagonist, which is in preclinical trial to treat vitiligo; and ACT-1004-1239, an ACKR3 receptor antagonist which is preclinical trial for the treatment of progressive multiple sclerosis. It also develops ACT-1016-0707, a LPA 1 receptor antagonist to treat immune-mediated and fibrosis related disorders; IDOR-1141-8472, an orexin 2 receptor agonist to treat orexin-related CNS disorders; and IDOR-1126-6421 to treat organ injury. The company holds a license agreement with Neuro to develop and commercialize clazosentan; collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; and collaboration with Viatris Inc. to develop and commercialize selatogrel and cenerimod. Idorsia Ltd was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
19T Stock 12 Month Forecast
Average Price Target
€6.18
▲(2.62% Upside)
Technical Analysis
Addex Therapeutics
―
Molecular Partners AG
―
Basilea Pharmaceutica
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―